Availability on request
AdipotideEffects observed in the Adipotide study: weight and body fat loss, as well as improvements in metabolic markers
2 mg · 10 vials
| Product code | AT-AP |
|---|---|
| Specification | 10 mg |
| Source SKU | AP10 |
| 10-vial kit | 10 vials |
Choose specification
| Product code | AT-AP |
|---|---|
| Specification | 10 mg |
| Source SKU | AP10 |
| 10-vial kit | 10 vials |
High-purity lyophilized research material with specification and batch documentation support from our team.
For laboratory research use only. Not for human or veterinary use.
Availability and shipping are confirmed after inquiry.
Availability on request
AdipotideEffects observed in the Adipotide study: weight and body fat loss, as well as improvements in metabolic markers
2 mg · 10 vialsAvailability on request
AICARKey Benefits of AICAR: Promotes glucose uptake by skeletal muscle, influences energy metabolism, and improves endurance,
50 mg · 10 vialsAvailability on request
TirzepatideTirzepatide is a once-weekly GIP+GLP-1 dual receptor agonist currently used primarily to treat type 2 diabetes and to assist with weight management in obese or overweight individuals. Its mechanism of action includes enhancing satiety, suppressing appetite, and improving glycemic control. Key Benefits: Significant weight loss; reduced appetite and increased satiety; lower blood glucose levels and improved hemoglobin A1c (HbA1c) levels; improved certain metabolic markers;
10 mg · 10 vialsAvailability on request
RetatrutideRetatrutide (development code LY3437943) is a triple receptor agonist currently under development that targets GIP, GLP-1, and glucagon (GCG) receptors simultaneously. It is primarily being investigated for the treatment of obesity, overweight, and related metabolic diseases. Key advantage: significant weight loss.
10 mg · 10 vials